Adaptive immune activation: Glycosylation does matter

Nature Chemical Biology

Volumn 9, Issue 12, 2013, Pages 776-784

  Wolfert, Margreet A ^a   Boons, Geert Jan ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BACTERIAL POLYSACCHARIDE; CANCER VACCINE; CD209 ANTIGEN; COLLAGEN TYPE 2; GALECTIN 1; GLYCAN; GLYCOPEPTIDASE; GLYCOSYLTRANSFERASE; LECTIN RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MUCIN 1; N ACETYLGLUCOSAMINE; PROTEIN KINASE SYK;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ANTIGEN RETRIEVAL; APOPTOSIS; AUTOIMMUNITY; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BINDING SITE; CANCER CELL; CANDIDA ALBICANS; CD4+ T LYMPHOCYTE; CELL INTERACTION; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURFACE; CELL TRANSFORMATION; CROSS REACTION; CYTOKINE RESPONSE; CYTOSOL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ELECTRON TRANSPORT; ENDOCYTOSIS; ENDOPLASMIC RETICULUM; GENE TARGETING; GOLGI COMPLEX; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; INTERNALIZATION; INTRACELLULAR SIGNALING; LEUKOCYTE ROLLING; LIGAND BINDING; MACROPHAGE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN GLYCOSYLATION; PROTEIN MODIFICATION; PROTEIN PROCESSING; REVIEW; SECRETORY PATHWAY; T LYMPHOCYTE;

ADAPTIVE IMMUNITY; ANTIGENS; GLYCOPROTEINS; GLYCOSYLATION; MAJOR HISTOCOMPATIBILITY COMPLEX; VACCINES;

EID: 84887987723     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1403     Document Type: Review

References (111)

1. Varki, A. Biological roles of oligosaccharides-all of the theories are correct. Glycobiology 3, 97-130 (1993).
2. Roth, J. Protein N-glycosylation along the secretory pathway: relationship to organelle topography and function, protein quality control, and cell interactions. Chem. Rev. 102, 285-303 (2002).
3. Kleene, R. & Schachner, M. Glycans and neural cell interactions. Nat. Rev. Neurosci. 5, 195-208 (2004).
4. Ohtsubo, K. & Marth, J.D. Glycosylation in cellular mechanisms of health and disease. Cell 126, 855-867 (2006).
5. Prescher, J.A. & Bertozzi, C.R. Chemical technologies for probing glycans. Cell 126, 851-854 (2006).
6. Lanctot, P.M., Gage, F.H. & Varki, A.P. The glycans of stem cells. Curr. Opin. Chem. Biol. 11, 373-380 (2007).
7. Taylor, M.E. & Drickamer, K. Paradigms for glycan-binding receptors in cell adhesion. Curr. Opin. Cell Biol. 19, 572-577 (2007).
8. Hart, G.W. & Copeland, R.J. Glycomics hits the big time. Cell 143, 672-676 (2010).
9. Hart, G.W., Slawson, C., Ramirez-Correa, G. & Lagerlof, O. Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. Annu. Rev. Biochem. 80, 825-858 (2011).
10. Brockhausen, I. Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions. EMBO Rep. 7, 599-604 (2006).
11. Brown, J.R., Crawford, B.E. & Esko, J.D. Glycan antagonists and inhibitors: a fount for drug discovery. Crit. Rev. Biochem. Mol. Biol. 42, 481-515 (2007).
12. Crocker, P.R., Paulson, J.C. & Varki, A. Siglecs and their roles in the immune system. Nat. Rev. Immunol. 7, 255-266 (2007).
13. Varki, A. Glycan-based interactions involving vertebrate sialic-acid- recognizing proteins. Nature 446, 1023-1029 (2007).
14. van Kooyk, Y. & Rabinovich, G.A. Protein-glycan interactions in the control of innate and adaptive immune responses. Nat. Immunol. 9, 593-601 (2008).
15. Freeze, H.H. Congenital disorders of glycosylation: CDG-I, CDG-II, and beyond. Curr. Mol. Med. 7, 389-396 (2007).
16. Rudd, P.M., Elliott, T., Cresswell, P., Wilson, I.A. & Dwek, R.A. Glycosylation and the immune system. Science 291, 2370-2376 (2001).
17. Baum, L.G. & Crocker, P.R. Glycoimmunology: ignore at your peril! Immunol. Rev. 230, 5-8 (2009).
18. Petersen, J., Purcell, A.W. & Rossjohn, J. Post-translationally modified T cell epitopes: immune recognition and immunotherapy. J. Mol. Med. 87, 1045-1051 (2009).
19. Avci, F.Y., Li, X., Tsuji, M. & Kasper, D.L. Carbohydrates and T cells: a sweet twosome. Semin. Immunol. 25, 146-151 (2013).
20. Anderton, S.M. Post-translational modifications of self antigens: implications for autoimmunity. Curr. Opin. Immunol. 16, 753-758 (2004).
21. Purcell, A.W., van Driel, I.R. & Gleeson, P.A. Impact of glycans on T-cell tolerance to glycosylated self-antigens. Immunol. Cell Biol. 86, 574-579 (2008).
22. Marth, J.D. & Grewal, P.K. Mammalian glycosylation in immunity. Nat. Rev. Immunol. 8, 874-887 (2008).
23. Ryan, S.O. & Cobb, B.A. Host glycans and antigen presentation. Microbes Infect. 14, 894-903 (2012).
24. Buskas, T., Ingale, S. & Boons, G.J. Glycopeptides as versatile tools for glycobiology. Glycobiology 16, 113R-136R (2006).
25. Calo, D., Kaminski, L. & Eichler, J. Protein glycosylation in Archaea: sweet and extreme. Glycobiology 20, 1065-1076 (2010).
26. Nothaft, H. & Szymanski, C.M. Protein glycosylation in bacteria: sweeter than ever. Nat. Rev. Microbiol. 8, 765-778 (2010).
27. Vigerust, D.J. & Shepherd, V.L. Virus glycosylation: role in virulence and immune interactions. Trends Microbiol. 15, 211-218 (2007).
28. Lizak, C., Gerber, S., Numao, S., Aebi, M. & Locher, K.P. X-ray structure of a bacterial oligosaccharyltransferase. Nature 474, 350-355 (2011).
29. Schwarz, F. & Aebi, M. Mechanisms and principles of N-linked protein glycosylation. Curr. Opin. Struct. Biol. 21, 576-582 (2011).
30. Taniguchi, N. & Korekane, H. Branched N-glycans and their implications for cell adhesion, signaling and clinical applications for cancer biomarkers and in therapeutics. BMB Rep. 44, 772-781 (2011).
31. Moremen, K.W., Tiemeyer, M. & Nairn, A.V. Vertebrate protein glycosylation: diversity, synthesis and function. Nat. Rev. Mol. Cell Biol. 13, 448-462 (2012).
32. Helenius, A. & Aebi, M. Intracellular functions of N-linked glycans. Science 291, 2364-2369 (2001).
33. Ellgaard, L. & Helenius, A. Quality control in the endoplasmic reticulum. Nat. Rev. Mol. Cell Biol. 4, 181-191 (2003).
34. Helenius, A. & Aebi, M. Roles of N-linked glycans in the endoplasmic reticulum. Annu. Rev. Biochem. 73, 1019-1049 (2004).
35. Bennett, E.P. et al. Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family. Glycobiology 22, 736-756 (2012).
36. Cummings, R.D. The repertoire of glycan determinants in the human glycome. Mol. Biosyst. 5, 1087-1104 (2009).
37. Nairn, A.V. et al. Regulation of glycan structures in animal tissues: transcript profiling of glycan-related genes. J. Biol. Chem. 283, 17298-17313 (2008).
38. Nairn, A.V. & Moremen, K.W. Handbook of Glycomics (eds. Cummings, R. & Pierce, J.M.) 95-136 (Academic Press, Burlington, MA, 2009).
39. Vyas, J.M., van der Veen, A.G. & Ploegh, H.L. The known unknowns of antigen processing and presentation. Nat. Rev. Immunol. 8, 607-618 (2008).
40. Neefjes, J., Jongsma, M.L., Paul, P. & Bakke, O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat. Rev. Immunol. 11, 823-836 (2011).
41. Basler, M., Kirk, C.J. & Groettrup, M. The immunoproteasome in antigen processing and other immunological functions. Curr. Opin. Immunol. 25, 74-80 (2013).
42. Garstka, M.A. & Neefjes, J. How to target MHC class II into the MIIC compartment. Mol. Immunol. 55, 162-165 (2013).
43. Batista, F.D. & Harwood, N.E. The who, how and where of antigen presentation to B cells. Nat. Rev. Immunol. 9, 15-27 (2009).
44. Trombetta, E.S. & Mellman, I. Cell biology of antigen processing in vitro and in vivo. Annu. Rev. Immunol. 23, 975-1028 (2005).
45. Taylor, M.E. & Drickamer, K. Structure-function analysis of C-type animal lectins. Methods Enzymol. 363, 3-16 (2003).
46. Sancho, D. & Reis e Sousa, C. Signaling by myeloid C-type lectin receptors in immunity and homeostasis. Annu. Rev. Immunol. 30, 491-529 (2012).
47. Plato, A., Willment, J.A. & Brown, G.D. C-type lectin-like receptors of the dectin-1 cluster: ligands and signaling pathways. Int. Rev. Immunol. 32, 134-156 (2013).
48. Osorio, F. & Reis e Sousa, C. Myeloid C-type lectin receptors in pathogen recognition and host defense. Immunity 34, 651-664 (2011).
49. Švajger, U., Anderluh, M., Jeras, M. & Obermajer, N. C-type lectin DC-SIGN: an adhesion, signalling and antigen-uptake molecule that guides dendritic cells in immunity. Cell. Signal. 22, 1397-1405 (2010).
50. Mitchell, D.A., Fadden, A.J. & Drickamer, K. A novel mechanism of carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR. Subunit organization and binding to multivalent ligands. J. Biol. Chem. 276, 28939-28945 (2001).
51. Dam, T.K. & Brewer, C.F. Lectins as pattern recognition molecules: the effects of epitope density in innate immunity. Glycobiology 20, 270-279 (2010).
52. García-Vallejo, J.J. et al. Multivalent glycopeptide dendrimers for the targeted delivery of antigens to dendritic cells. Mol. Immunol. 53, 387-397 (2013).
53. van Kooyk, Y., Unger, W.W., Fehres, C.M., Kalay, H. & Garcia-Vallejo, J.J. Glycan-based DC-SIGN targeting vaccines to enhance antigen crosspresentation. Mol. Immunol. 55, 143-145 (2013).
54. Johnson, M.A. & Bundle, D.R. Designing a new antifungal glycoconjugate vaccine. Chem. Soc. Rev. 42, 4327-4344 (2013).
55. Lipinski, T. et al. Enhanced immunogenicity of a tricomponent mannan tetanus toxoid conjugate vaccine targeted to dendritic cells via Dectin-1 by incorporating β-glucan. J. Immunol. 190, 4116-4128 (2013).
56. Hanisch, F.G. & Ninkovic, T. Immunology of O-glycosylated proteins: approaches to the design of a MUC1 glycopeptide-based tumor vaccine. Curr. Protein Pept. Sci. 7, 307-315 (2006).
57. Doe, B., Steimer, K.S. & Walker, C.M. Induction of HIV-1 envelope (gp120)- specific cytotoxic T lymphocyte responses in mice by recombinant CHO cell-derived gp120 is enhanced by enzymatic removal of N-linked glycans. Eur. J. Immunol. 24, 2369-2376 (1994).
58. Li, H. et al. Proximal glycans outside of the epitopes regulate the presentation of HIV-1 envelope gp120 helper epitopes. J. Immunol. 182, 6369-6378 (2009).
59. Ninkovic, T. & Hanisch, F.G. O-glycosylated human MUC1 repeats are processed in vitro by immunoproteasomes. J. Immunol. 179, 2380-2388 (2007)..
60. Werdelin, O., Meldal, M. & Jensen, T. Processing of glycans on glycoprotein and glycopeptide antigens in antigen-presenting cells. Proc. Natl. Acad. Sci. USA 99, 9611-9613 (2002).
61. Kario, E., Tirosh, B., Ploegh, H.L. & Navon, A. N-linked glycosylation does not impair proteasomal degradation but affects class I major histocompatibility complex presentation. J. Biol. Chem. 283, 244-254 (2008).
62. Altrich-VanLith, M.L. et al. Processing of a class I-restricted epitope from tyrosinase requires peptide N-glycanase and the cooperative action of endoplasmic reticulum aminopeptidase 1 and cytosolic proteases. J. Immunol. 177, 5440-5450 (2006)..
63. Dengjel, J. & Stevanovic, S. Naturally presented MHC ligands carrying glycans. Transfus. Med. Hemother. 33, 38-44 (2006).
64. Jensen, T. et al. Carbohydrate and peptide specificity of MHC class IIrestricted T cell hybridomas raised against an O-glycosylated self peptide. J. Immunol. 158, 3769-3778 (1997).
65. Bäcklund, J. et al. Predominant selection of T cells specific for the glycosylated collagen type II epitope (263-270) in humanized transgenic mice and in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 99, 9960-9965 (2002).
66. Andersson, I.E. et al. Design of glycopeptides used to investigate class II MHC binding and T-cell responses associated with autoimmune arthritis. PLoS ONE 6, e17881 (2011).
67. Dzhambazov, B. et al. Therapeutic vaccination of active arthritis with a glycosylated collagen type II peptide in complex with MHC class II molecules. J. Immunol. 176, 1525-1533 (2006).
68. Apostolopoulos, V. et al. A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor. Proc. Natl. Acad. Sci. USA 100, 15029- 15034 (2003).
69. Tarp, M.A. & Clausen, H. Mucin-type O-glycosylation and its potential use in drug and vaccine development. Biochim. Biophys. Acta 1780, 546-563 (2008).
70. Roulois, D., Gregoire, M. & Fonteneau, J.F. MUC1-specific cytotoxic T lymphocytes in cancer therapy: induction and challenge. Biomed. Res. Int. doi:10.1155/2013/871936 (2012).
71. Haurum, J.S. et al. Presentation of cytosolic glycosylated peptides by human class I major histocompatibility complex molecules in vivo. J. Exp. Med. 190, 145-150 (1999).
72. Vlad, A.M. et al. Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class IIrestricted T cells. J. Exp. Med. 196, 1435-1446 (2002).
73. Stepensky, D., Tzehoval, E., Vadai, E. & Eisenbach, L. O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma. Clin. Exp. Immunol. 143, 139-149 (2006).
74. Beatson, R.E., Taylor-Papadimitriou, J. & Burchell, J.M. MUC1 immunotherapy. Immunotherapy 2, 305-327 (2010).
75. Kimura, T. & Finn, O.J. MUC1 immunotherapy is here to stay. Expert Opin. Biol. Ther. 13, 35-49 (2013).
76. Coltart, D.M. et al. Principles of mucin architecture: structural studies on synthetic glycopeptides bearing clustered mono-, di-, tri-, and hexasaccharide glycodomains. J. Am. Chem. Soc. 124, 9833-9844 (2002).
77. Karsten, U., Serttas, N., Paulsen, H., Danielczyk, A. & Goletz, S. Binding patterns of DTR-specific antibodies reveal a glycosylation-conditioned tumor-specific epitope of the epithelial mucin (MUC-1). Glycobiology 14, 681-692 (2004).
78. Dziadek, S., Griesinger, C., Kunz, H. & Reinscheid, U.M. Synthesis and structural model of an a(2,6)-sialyl-t glycosylated MUC1 eicosapeptide under physiological conditions. Chemistry 12, 4981-4993 (2006).
79. Lakshminarayanan, V. et al. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proc. Natl. Acad. Sci. USA 109, 261-266 (2012).
80. Gaidzik, N., Westerlind, U. & Kunz, H. The development of synthetic antitumour vaccines from mucin glycopeptide antigens. Chem. Soc. Rev. 42, 4421-4442 (2013).
81. Wells, L. & Hart, G.W. Glycomics: building upon proteomics to advance glycosciences. Mol. Cell. Proteomics 12, 833-835 (2013).
82. Steentoft, C. et al. Mining the O-glycoproteome using zinc-finger nucleaseglycoengineered SimpleCell lines. Nat. Methods 8, 977-982 (2011).
83. Avci, F.Y., Li, X., Tsuji, M. & Kasper, D.L. A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nat. Med. 17, 1602-1609 (2011).
84. Costantino, P., Rappuoli, R. & Berti, F. The design of semi-synthetic and synthetic glycoconjugate vaccines. Expert Opin. Drug Discov. 6, 1045-1066 (2011).
85. Lai, Z. & Schreiber, J.R. Antigen processing of glycoconjugate vaccines; the polysaccharide portion of the pneumococcal CRM(197) conjugate vaccine co-localizes with MHC II on the antigen processing cell surface. Vaccine 27, 3137-3144 (2009).
86. Johnson, J.L., Jones, M.B., Ryan, S.O. & Cobb, B.A. The regulatory power of glycans and their binding partners in immunity. Trends Immunol. 34, 290-298 (2013).
87. Barthel, S.R., Gavino, J.D., Descheny, L. & Dimitroff, C.J. Targeting selectins and selectin ligands in inflammation and cancer. Expert Opin. Ther. Targets 11, 1473-1491 (2007).
88. Liu, F.T. Regulatory roles of galectins in the immune response. Int. Arch. Allergy Immunol. 136, 385-400 (2005).
89. Vasta, G.R. Roles of galectins in infection. Nat. Rev. Microbiol. 7, 424-438 (2009).
90. Garner, O.B. & Baum, L.G. Galectin-glycan lattices regulate cell-surface glycoprotein organization and signalling. Biochem. Soc. Trans. 36, 1472-1477 (2008).
91. Liu, S.D. et al. Endogenous galectin-1 enforces class I-restricted TCR functional fate decisions in thymocytes. Blood 112, 120-130 (2008).
92. Perillo, N.L., Pace, K.E., Seilhamer, J.J. & Baum, L.G. Apoptosis of T cells mediated by galectin-1. Nature 378, 736-739 (1995).
93. Hsu, D.K., Chen, H.Y. & Liu, F.T. Galectin-3 regulates T-cell functions. Immunol. Rev. 230, 114-127 (2009).
94. Demetriou, M., Granovsky, M., Quaggin, S. & Dennis, J.W. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature 409, 733-739 (2001).
95. Chen, I.J., Chen, H.L. & Demetriou, M. Lateral compartmentalization of T cell receptor versus CD45 by galectin-N-glycan binding and microfilaments coordinate basal and activation signaling. J. Biol. Chem. 282, 35361-35372 (2007).
96. Clark, M.C. & Baum, L.G. T cells modulate glycans on CD43 and CD45 during development and activation, signal regulation, and survival. Ann. NY Acad. Sci. 1253, 58-67 (2012).
97. Tribulatti, M.V., Cattaneo, V., Hellman, U., Mucci, J. & Campetella, O. Galectin-8 provides costimulatory and proliferative signals to T lymphocytes. J. Leukoc. Biol. 86, 371-380 (2009).
98. Poe, J.C. & Tedder, T.F. CD22 and Siglec-G in B cell function and tolerance. Trends Immunol. 33, 413-420 (2012).
99. Collins, B.E., Smith, B.A., Bengtson, P. & Paulson, J.C. Ablation of CD22 in ligand-deficient mice restores B cell receptor signaling. Nat. Immunol. 7, 199-206 (2006).
100. Hennet, T., Chui, D., Paulson, J.C. & Marth, J.D. Immune regulation by the ST6Gal sialyltransferase. Proc. Natl. Acad. Sci. USA 95, 4504-4509 (1998).
101. Courtney, A.H., Puffer, E.B., Pontrello, J.K., Yang, Z.Q. & Kiessling, L.L. Sialylated multivalent antigens engage CD22 in trans and inhibit B cell activation. Proc. Natl. Acad. Sci. USA 106, 2500-2505 (2009).
102. Duong, B.H. et al. Decoration of T-independent antigen with ligands for CD22 and Siglec-G can suppress immunity and induce B cell tolerance in vivo. J. Exp. Med. 207, 173-187 (2010);
103. erratum 207, 445 (2010).
104. Pilobello, K.T. & Mahal, L.K. Deciphering the glycocode: the complexity and analytical challenge of glycomics. Curr. Opin. Chem. Biol. 11, 300-305 (2007).
105. Vanderschaeghe, D., Festjens, N., Delanghe, J. & Callewaert, N. Glycome profiling using modern glycomics technology: technical aspects and applications. Biol. Chem. 391, 149-161 (2010).
106. Kolarich, D., Lepenies, B. & Seeberger, P.H. Glycomics, glycoproteomics and the immune system. Curr. Opin. Chem. Biol. 16, 214-220 (2012).
107. Haslam, S.M. et al. Characterizing the glycome of the mammalian immune system. Immunol. Cell Biol. 86, 564-573 (2008).
108. Rillahan, C.D. & Paulson, J.C. Glycan microarrays for decoding the glycome. Annu. Rev. Biochem. 80, 797-823 (2011).
109. Smith, D.F. & Cummings, R.D. Application of microarrays for deciphering the structure and function of the human glycome. Mol. Cell. Proteomics 12, 902-912 (2013).
110. Wang, Z. et al. A general strategy for the chemoenzymatic synthesis of asymmetrically branched N-glycans. Science 341, 379-383 (2013).
111. Han, S., Collins, B.E., Bengtson, P. & Paulson, J.C. Homomultimeric complexes of CD22 in B cells revealed by protein-glycan cross-linking. Nat. Chem. Biol. 1, 93-97 (2005).